Absci Corporation (ABSI) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The company's earnings call reflects positive financial performance, with increased cash reserves and reduced expenses. The strategic focus on advancing clinical trials and potential new partnerships, especially with large pharma, is promising. Despite some management vagueness, the Q&A session highlights optimism in drug development and partnerships, particularly for ABS-101 and ABS-201. The financial health and strategic partnerships suggest a positive stock price movement, although the lack of specific market cap data tempers expectations from a strong positive rating.
Key Financial Performance
Revenue $400,000 for the third quarter, with no year-over-year change mentioned.
Research and Development Expenses $19.2 million for the three months ended September 30, 2025, compared to $18 million for the prior year period, representing an increase. The increase was primarily driven by advancement of Absci's internal programs, including direct costs associated with external, preclinical, and clinical development.
Selling, General, and Administrative Expenses $8.4 million for the three months ended September 30, 2025, compared to $9.3 million for the prior year period, representing a decrease. The decrease was primarily due to a decrease in personnel-related expenses.
Cash, Cash Equivalents, and Marketable Securities $152.5 million as of September 30, 2025, compared to $117.5 million as of June 30, 2025, showing an increase. The increase was attributed to the company's financial management and operations.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
ABS-101 Phase I trial: Interim results showed extended half-life compared to first-generation anti-TL1A competitors, favorable safety profile, and no serious adverse events. Phase I trial to complete in Q1 2026.
ABS-201 for androgenetic alopecia (AGA): Phase I/IIa trial to start in December 2025, with interim proof-of-concept readout in H2 2026. Designed for durable hair regrowth with fewer injections compared to current treatments.
ABS-201 for endometriosis: Phase II trial to start in Q4 2026, targeting a significant unmet need in a multibillion-dollar market. Preclinical data supports its potential as a safe and effective therapy.
Market opportunity for ABS-201: Both AGA and endometriosis represent multibillion-dollar markets with high unmet needs. ABS-201 is positioned as a potential best-in-class therapy.
Strategic focus on ABS-201: Prioritizing ABS-201 development for AGA and endometriosis, reallocating resources from ABS-101. Seeking partnerships for ABS-101 and other programs.
AI platform capabilities: Expanding AI platform to support preclinical R&D and generate partnership interest. Anticipating new drug creation partnerships by year-end.
Pipeline prioritization: Focusing on ABS-201 for AGA and endometriosis due to their significant market potential and unmet needs. Seeking partners for ABS-101 and oncology programs.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
ABS-101 Phase I Results: Interim results showed extended half-life compared to first-generation competitors but not next-generation programs. No serious adverse events reported, but the program will no longer be pursued internally after Phase I due to resource reallocation.
ABS-201 Development Prioritization: The company is reallocating resources to prioritize ABS-201 development for androgenetic alopecia (AGA) and endometriosis, which could strain resources and delay other programs.
Regulatory and Clinical Development Risks: ABS-201's dual development in AGA and endometriosis involves complex clinical trials with potential regulatory hurdles and risks of delays or failures in achieving proof-of-concept.
Market Competition: ABS-201 faces competition from existing treatments like minoxidil and finasteride for AGA and HMI-115 for endometriosis, which could impact market adoption.
Financial Sustainability: While the company has cash reserves to fund operations into 2028, reliance on potential partnerships and asset transactions introduces financial uncertainty.
Pipeline Diversification Challenges: Focus on ABS-201 may limit progress on other pipeline programs like ABS-301 and ABS-501, which are dependent on external partnerships for advancement.
AI Platform Utilization: The company’s AI platform is critical for drug discovery, but its success depends on securing partnerships and demonstrating tangible outcomes.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
ABS-101 Phase I Trial: The Phase I trial for ABS-101 is on track to complete in Q1 of 2026. The company will seek a partner for ABS-101 and will not pursue additional internal clinical development for this asset after the trial's completion.
ABS-201 Development for Androgenetic Alopecia (AGA): The Phase I/IIa trial for ABS-201 in AGA is expected to begin in December 2025, with an interim proof-of-concept readout anticipated in the second half of 2026. The trial will assess safety, tolerability, PK, PD, and efficacy endpoints, including hair regrowth.
ABS-201 Development for Endometriosis: ABS-201 is being developed for endometriosis, with a Phase II proof-of-concept clinical trial expected to begin in Q4 of 2026. An interim data readout is anticipated in the second half of 2027. The development leverages shared Phase I data from the AGA trial.
Market Opportunities for ABS-201: Both AGA and endometriosis represent multibillion-dollar market opportunities. ABS-201 is positioned as a potential best-in-class therapy for both indications, addressing significant unmet medical needs and poor standard of care.
AI Platform and Partnerships: The company anticipates signing one or more drug creation partnerships, including with a large pharma company, by the end of 2025. These partnerships are expected to generate nondilutive cash inflows.
Financial Outlook: Cash, cash equivalents, and marketable securities as of September 30, 2025, were $152.5 million, sufficient to fund operations into the first half of 2028. Additional upside is expected from potential partnerships and asset transactions.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What details can you share about the TL1A program, specifically regarding the half-life or other trial observations?
A:The safety profile of ABS-101 was satisfactory, and the half-life extended beyond first-generation competitors but fell short of second-generation ones. The company decided to reinvest in ABS-201 for endometriosis due to the competitive landscape in IBD and the unmet medical need in endometriosis.
Q:What is the competitive landscape for endometriosis, and how will the Phase II trial be designed?
A:The endometriosis indication is less competitive than Crohn's, and the trial costs are lower. The ABS-201 mechanism has the potential to address pain and be disease-modifying. The company is working with KOLs and will share the draft study design in the new year.
Q:Have potential partners seen the data for ABS-101, and what is the feedback?
A:The data has not yet been shared with partners but will be in the coming weeks. Discussions about first-in-class indications for ABS-101 have been positive.
Q:How will the company address enrollment challenges in the endometriosis trial?
A:The company plans to enroll patients confirmed to have endometriosis and significant pain, addressing challenges seen in the HMI-115 study. Leading KOLs are advising on the trial design.
Q:What is the company's confidence in partnering ABS-101, and what are they looking for in a partner?
A:The company seeks partners with domain expertise and the ability to develop ABS-101 in specific indications. They are optimistic about partnering due to the expanded buyer universe and ongoing discussions.
Q:What is the recruitment strategy and cost for the alopecia trial, and how long will patients need to be on the drug?
A:Recruitment is expected to be on time with multiple sites in Australia. An interim readout is planned for early in the second half of next year, with efficacy measured at 13, 20, and 24 weeks.
Q:What are the features of TL1A, and why are alternative indications being considered?
A:The molecule is safe and well-tolerated, with no ADA effect on PK. Tissue distribution may lead to better efficacy in certain indications, prompting exploration of new first-in-class indications.
Q:Will the endometriosis trial use subcutaneous or intravenous dosing?
A:The Phase II trial for endometriosis will use subcutaneous dosing, similar to the AGA trial.
Q:Is the focus on both AGA and endometriosis, or is one taking precedence?
A:Both AGA and endometriosis are co-leads. The focus is on achieving a Phase II readout for AGA next year and endometriosis the following year.
Q:Will the company wait for alopecia data before starting the endometriosis trial?
A:The company plans to start the endometriosis trial after the SAD safety portion of the AGA trial, without waiting for the AGA readout.
Q:What learnings from HOPE Medicine's 115 trial are being applied to the 201 program?
A:The HMI-115 trial showed a dose response and statistically significant pain reduction in dysmenorrhea. The company plans to design a well-structured and adequately powered trial, learning from the HMI-115 trial's design issues.
Q:Are the ex vivo results for 201 better than expected, and can 201 be expanded to other indications?
A:The ex vivo results validated the mechanism and were consistent across patients. The company sees potential for expanding 201 to additional indications but is currently focused on AGA and endometriosis.
Q:Will 201 target all endometriosis patients, and what are the hurdles in the space?
A:201 is expected to work for all endometriosis patients due to its mechanism. The goal is to provide a non-hormonal, effective treatment option, addressing the limitations of current GnRH therapies.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details about the draft study design for the endometriosis trial, the exact cost of trials, and the timeline for sharing data with partners. They also used vague language when discussing the potential additional indications for 201 and the hurdles in the endometriosis space.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ABS AGA
ABS Phase
ABS development
ABS potential
ABS program
AGA endometriosis
American
Dermatology
Dr
HMI
II development
KOL
PK
Phase II
Phase IIa
Phase trial
RD
animal study
compliance
development endometriosis
dollar market
endometriosis ABS
formation
lesion
market opportunity
mechanism action
minoxidil
mouse
multibillion dollar
need standard
pain
portion trial
prolactin
research
seminar
standard care
th
trial AGA
woman
ABSI Transcript
Absci Corporation (ABSI) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Neutral6-10
Absci Corporation (ABSI) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
Neutral6-5
Absci Corporation (ABSI) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call highlights promising developments, such as the potential $25 billion market for ABS-201, strong consumer interest, and strategic focus on I&I over oncology. The company's confidence in achieving receptor occupancy and the efficient use of agentic AI for cost reduction further strengthen the outlook. Despite some withheld details, the overall sentiment is positive, with expectations of significant growth and market impact.
Absci Corporation (ABSI) Q4 2025 Earnings Call Transcript
Unknown3-24
The earnings call presents a mixed outlook. The company is actively pursuing partnerships and has a promising pipeline, which is positive. However, there are uncertainties, such as lack of FDA engagement on ABS-201's Phase III design and undisclosed pricing strategies, which create concerns. The market opportunity is significant, but the absence of clear guidance tempers optimism.
ABSI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
